Vitrakvi deemed ‘not cost-effective’ by NICE

17th January 2020 Uncategorised 0

The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.

More: Vitrakvi deemed ‘not cost-effective’ by NICE
Source: News